INTRODUCTION
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Se status did affect some measures of cell-mediated immune function in the adult horse (Brummer et al., 2009 (Brummer et al., , 2011 . Therefore, the aim of this study was to evaluate the effect of Se status and source of supplementation on vaccination response and immune function of the horse. The first objective was to determine if Se status affected the primary response to vaccination with a novel antigen (ovalbumin, OVA) and memory response to an equine influenza vaccine. Measures of vaccine response included both humoral and cell-mediated components of the immune system (i.e., antigen-specific antibody production, lymphocyte proliferation, intracellular cytokine production, and cytokine mRNA expression in response to antigen stimulation in vitro). The second objective was to determine if cell-mediated immune function was affected by Se status using in vitro cell cultures stimulated with nonspecific mitogens. Immune function was assessed using lymphocyte proliferation, intracellular cytokine production, and cytokine mRNA expression by peripheral blood mononuclear cells (PBMC). Unstimulated whole blood mRNA cytokine expression was used to assess in vivo cytokine expression. We hypothesized that horses of low Se status would have diminished immune function, contributing to a poor vaccine response.
MATERIALS AND METHODS
This research project was approved by the Institutional Animal Care and Use Committee of the University of Kentucky.
Animals
Twenty-eight mature horses, aged 5 to 23 yr, were used in this study and included 8 geldings and 20 mares. The geldings consisted of 6 Thoroughbreds, 1 American Quarter Horse, and 1 Standardbred, and the mares consisted of 19 Thoroughbreds and 1 American Quarter Horse.
Experimental Design, Diets, and Treatments
The 28 horses were blocked by age and sex and randomly allocated within block to 1 of 4 dietary Se treatments: a low-Se group (LS), adequate-Se group (AS), an organic Se group (SP; Sel-Plex; Alltech Inc., Nicholasville, KY), and an inorganic Se group (SS; sodium selenite; Retorte Aurubis Group, Waltham, MA). Throughout the study, the horses were kept on 6 pastures but were allocated to pasture so that all treatments were represented in each pasture. Pastures were sampled on a monthly basis until pasture availability was too low to sample. The Se content of the pastures fluctuated but remained marginal in Se (0.03 to 0.07 mg/kg DM; Table   1 ). When pasture availability declined in winter, horses were fed hay that was produced on the same farm (0.06 mg Se/kg DM) and cracked corn (<0.16 mg Se/kg DM) to maintain an adequate calorie intake. Horses had ad libitum access to water and an iodized salt block. Horses were weighed on a monthly basis by means of a portable, large-animal scale (TI-500BWL; Trancell Technology, Buffalo Grove, IL), and BW was used to calculate supplementation rates. Custom-formulated adequate-Se (2.52 mg Se/kg DM) or low-Se (0.53 mg Se/kg DM) protein-vitamin-mineral balancer pellets (Table 1 ; McCauley Bros. Inc., Versailles, KY) were fed to meet the trace mineral requirements of each horse above that provided by pasture. For 35 wk, horses assigned to the LS, SP, and SS groups were fed a low-Se diet containing 0.06 mg Se/kg DM, and the AS group received an adequate-Se diet containing 0.12 mg Se/kg DM.
A 29-wk repletion phase followed the depletion phase. Horses originally assigned to AS and LS remained on their respective diets, whereas horses on SP and SS treatments were provided with additional Se supplements. The Se supplements were top dressed on the balancer pellet. To account for the yeast component in the Se-yeast supplement, the same strain of brewer's yeast was used as the carrier for the sodium selenite supplement. Horses on the AS and LS treatments re- ceived the brewer's yeast carrier only. This allowed for a similar brewer's yeast intake among the 4 treatment groups. A small amount of water was added to the balancer pellet and top-dressed supplement before feeding to improve the palatability and texture. The horses were closely monitored to ensure that the allotted supplement and balancer pellet was completely consumed. During the repletion phase, the total dietary Se intakes were calculated to be 0.06 mg Se/kg DM for LS and 0.12 mg Se/kg DM for AS. Horses on the SP and SS treatments received additional Se from their respective dietary Se supplements to allow for a total dietary Se concentration 0.3 mg Se/kg DM. Total dietary Se intake was calculated to be equal among horses within treatment on a BW basis.
The horses were kept on their respective diets for 22 wk before the onset of the vaccine challenge. This period was selected to ensure that the turnover of circulating red blood cells (140 to 150 d) would be sufficient to identify change in Se status through measurements of whole blood Se and glutathione peroxidase (GSH-Px) activity. Horses remained on the same diets throughout the 7-wk vaccine challenge. Before the vaccine challenge 2 Thoroughbred mares and 1 gelding had to be removed from the study because of unrelated medical reasons. Therefore, the AS, LS, and SS groups consisted of 6 horses each, and the SP group consisted of 7 horses.
Blood Sampling
Blood samples were collected before the start of the repletion phase and every 4 wk thereafter to monitor Se status. During the vaccine challenge, blood samples were collected before vaccination and at 2, 3, 4, 5, 6, and 7 wk postvaccination to monitor immune response. All blood samples were obtained via jugular venipuncture. Blood was collected in 7-mL lithium heparin blood collection tubes (Becton Dickson, Franklin Lakes, NJ) for analysis of whole blood Se and GSH-Px activity. Blood was also collected in untreated blood collection tubes for serum separation (Becton Dickson) and EDTA-containing tubes (Becton Dickson) for complete blood count (CBC) analysis. During the vaccine challenge, additional blood samples were collected to assess PBMC. For the isolation of PBMC, blood was collected in 15-mL, sodium heparin (Wickliff Veterinary Pharmacy, Lexington, KY) treated (100 μL per tube) vacutainer tubes (Monoject Blood Collection Tubes; Kendall, Mansfield, MA).
Vaccine Challenge
After completion of the 22-wk repletion period, a novel vaccine challenge was used to assess immune response. The vaccine challenge was completed over 7 wk. Vaccination and sampling time points for the vaccine challenge are described in Fig. 1 . The OVA (Sigma, Saint Louis, MO) vaccines were prepared under sterile conditions in a laminar flow hood (Biological Safety Cabinets; NuAire, Plymouth, MN). The OVA was dissolved in sterile physiological saline (Butler, Lexington, KY) at a concentration appropriate to allow the final vaccine volume to be 1 mL (i.e., 10 mg OVA/mL). The vaccine was administered intramuscularly in the pectoral muscle after thorough cleaning of the area with ethanol.
Prevaccination blood samples were collected immediately before the first vaccination. Horses were then vaccinated with 10 mg OVA (Sigma) followed by a second 10 mg OVA injection 3 wk later (wk 25). Horses were also vaccinated against equine influenza strain KY2002 (Prestige V; Intervet, Summit, NJ) at the time of the second OVA vaccine [i.e., 3 wk after the initial OVA vaccine (wk 25)] to evaluate memory immune response. This vaccine was selected as all horses were vaccinated with this vaccine 8 mo before. All horses were therefore expected to display a memory response to the KY2002 influenza strain. The influenza vaccine was administered intramuscularly in the neck, again after thorough cleaning of the vaccination area with ethanol.
Laboratory Procedures: Se Status and Complete Blood Count Analysis
Whole blood Se concentration was determined by the Diagnostic Center for Population and Animal Health (Michigan State University, Lansing, MI) by means of inductively coupled plasma-mass spectroscopy (Hall et al., 2012) . Whole blood GSH-Px activity was determined using a kit (Bioxytech GPx-340 Assay Kit; OXIS Research, Portland, OR; Richardson et al., 2006) based on the method developed by Paglia and Valentine (1967) . The GSH-Px activity of each sample was calculated from the change in absorbance and expressed as units of enzyme activity per milligram of hemoglobin.
The CBC analyses were performed by a local commercial equine hospital (Rood and Riddle Equine Hospital, Lexington, KY; Morresey and Waldridge, 2010) . The numbers of lymphocytes and neutrophils were then calculated from the results of the analysis.
Laboratory Procedure: Immune Response Assays
In Vitro and In Vivo Cytokine Evaluation. The PBMC were isolated using a medium and gradient centrifugation (Ficoll-Paque Plus; Amersham Biosciences, Piscataway, NJ). Approximately 30 mL of plasma were layered on top of 10 mL of medium (Ficoll-Paque Plus) and centrifuged at 500 × g for 30 min at 4°C. Interface cells were collected, washed 3 times with PBS (Sigma), counted (Vi-cell Counter; Beckman Coulter, Miami, FL), and resuspended at the required concentrations for each assay in a medium (RPMI 1640; Gibco, Grand Island, NY) . The medium (RPMI 1640) was supplemented with 2 mM l-glutamine (Sigma), 100 U/mL penicillin/streptomycin (Sigma), 55 μM 2-mercaptoethanol (Gibco), and 2.5% heat-inactivated autologous serum. Autologous serum was used so that the PBMC from each horse were incubated in media containing its own serum, especially as serum Se concentration would vary between horses on different dietary treatments. Autologous serum was heat inactivated as described by Lessard et al. (1991) .
The PBMC were plated in 3.5 mL culture wells (TPP, Trasadingen, Switzerland) at a final concentration of 4 × 10 6 cells/mL. Four culture wells were prepared per horse for in vitro stimulation of cells: media alone (control); phorbol 12-myristate 13-acetate (PMA; 25 ng/mL) and ionomycin (1 μM), added for the last 4 h of incubation; OVA (5 μg/mL); and equine influenza virus. The equine influenza virus (KY2002) that was used for in vitro cell culture stimulation was prepared using 10-dold embryonated chicken eggs as described by Adams et al. (2011) . Before plating, PBMC to be stimulated with equine influenza virus (KY2002) were transferred to microcentrifuge tubes and incubated in a 37°C water bath for 45 min with KY2002 virus at a multiplicity of infection of 1. After incubation, the influenza-stimulated PBMC were centrifuged (300 × g for 5 min at 4°C), and the PBMC pellet was suspended in the supplemented media. After adding PBMC to the cell culture wells the plates were placed in a 37°C, 5% CO 2 humidified incubator for 20 h. Brefeldin A (2 μL/well) was then added to all cell cultures. At this time the PMA and ionomycin (10 μL/well) were also added to the PMA wells, and all PBMC were incubated for an additional 4 h. After a total incubation period of 24 h, 2 × 10 6 PBMC from each culture were used for intracellular staining for interferon-γ (IFNγ) and tumor necrosis factor-α (TNFα) using a flow cytometer, and in vitro mRNA expression of cytokines was measured on the remaining stimulated PBMC using RT-PCR as described by Breathnach et al. (2006) .
Intracellular staining was performed to assess IFNγ and TNFα production, as previously described (Breathnach et al., 2006; Adams et al., 2009) . The stained cells were analyzed using a flow cytometer (FACSCalibur; Becton Dickson). With Cell Quest software (Becton Dickson), markers were placed on the unstimulated (media alone) cells so that 1% of the cells were IFNγ or TNFα positive. These markers were then used to analyze the stimulated cells. The percentage of lymphocytes, identified and gated on the basis of the forward and side scatter parameters, producing IFNγ or TNFα was calculated. The mean fluorescence intensity (MFI) was determined as a measure of the amount of cytokine produced as indicated by the intensity of the IFNγ or TNFα signal (Breathnach et al., 2006) . The PBMC stimulated as described above were used to assess the in vitro gene expression of granzyme B (GrzB), IL-1, IL-2, IL-6, IL-8, IL-10, IL-13, IFNγ, and TNFα. In addition, the gene expression of 2 transcription factors, GATA binding protein-3 (GATA-3) and T-box expressed in T cells (T-bet), were also assessed. The transcription factor GATA-3 belongs to the GATA family, which binds to consensus DNA sequence A/T; GATA A/G (Chakir et al., 2003) , whereas T-bet belongs to the T-box family of transcription factors (Szabo et al., 2000) . These 2 transcription factors play key roles in the expression of the T helper cytokine genes associated with defense against extracellular and intracellular pathogens, respectively (Chakir et al., 2003) . After in vitro stimulation, 2 × 10 6 cells were lysed by the addition of 1 mL RNA-STAT 60 (Tel-Test; Isotex Diagnostics Inc., Friendswood, TX) and stored at -80°C until total RNA was extracted using the manufacturer's protocol. The relative quantity of cytokine gene expression was determined by means of real-time PCR (Applied Biosystems, Foster City, CA) using equine-specific intron spanning primer/probe sets (Applied Biosystems) as previously described (Breathnach et al., 2006; Adams et al., 2009 Adams et al., , 2011 Saulez et al., 2010; Soboll Hussey et al., 2011) . The relative change in gene expression was calculated as described in Livak and Schmittgen (2001) , and results were expressed as the relative quantity calculated as 2 -ΔΔCT (where CT is threshold cycle) with the unstimulated PBMC serving as calibrators for stimulated samples. The β-glucuronidase was used as the internal control (Breathnach et al., 2006) .
In vivo mRNA expression of IFNγ, TNFα, IL-6, IL-8, and IL-10 in unstimulated whole blood was assessed by collecting 2.5 mL of blood via jugular venipuncture into PAXgene blood RNA tubes (PreAnalytiX, Valencia, CA). Total RNA was extracted using the PAXgene RNA extraction kit (Qiagen, Valencia, CA), according to the manufacturer's protocol. Reverse transcription was conducted as described by Breathnach et al. (2006) . The RT-PCR was performed and the relative quantity of mRNA was calculated as described before for the stimulated PBMC. Samples taken before the onset of the dietary supplementation period were analyzed, and the mean for each cytokine was calculated and used as the calibrator. Lymphocyte Proliferation. The 3 H-thymidine incorporation method was used to evaluate lymphocyte proliferation. Isolated PBMC were plated at a concentration of 2 × 10 6 cells/mL in 96-well flat-bottom plates (TPP). Again, 4 cultures were set up in triplicate for each horse: media alone (control), concanavalin A (ConA; 10 μg/mL) as mitogen to stimulate proliferation (Lis and Sharon, 1998) , OVA (25 μg/mL), and equine influenza. To evaluate proliferation in response to influenza virus, PBMC stimulated with the purified equine influenza virus KY2002 as described before were added to wells containing media alone. After a 72-h incubation period in a 37°C, 5% CO 2 humidified incubator, PBMC were pulsed with 0.5 μCi 3 H-thymidine, incubated for an additional 18-h period, and frozen (-20°C). The DNA was extracted from the cells onto fiber filter pads (Perklin Elmer Inc., Waltham, MA) using a harvester (Tomtec; J/B Industries Inc., Aurora, IL), and liquid scintillation counting was performed (Wallac Inc., Gaithersburg, MD). The results are reported as the stimulation index of corrected counts per minute of stimulated cells, divided by the corrected counts per minute for control cells.
Antibody Production: OVA-Specific ELISA. Serum OVA-specific antibody concentrations were measured by means of an ELISA assay. Briefly, Immulon 1B microtiter plates (Fisher Scientific, Hanover Park, IL) were coated overnight at 4°C with 300 μg OVA/mL. The next day, plates were washed with PBS/0.05% TWEEN-20 (PBS-T; Sigma) and blocked with PBS containing 0.5% polyvinyl alcohol (Sigma). Serum samples were diluted 1:300 in PBS-T and added to wells in triplicate. Plates were incubated at 37°C for 1 h. After washing plates with PBS-T, the secondary antibody, peroxidase (Conjugated AffiniPure Goat Anti-Horse IgG; Jackson Immuno Research, West Grove, PA) was added to each well at a dilution of 1:2,500. After incubation at 37°C for 1 h plates were washed using PBS-T, and substrate (3,3′,5,5′-tetramethylbenzidine; Sureblue TMB 1; KPL, Gaithersburg, MD) was added. Color was developed for 30 s before the reaction was stopped (TMB Stop Solution; KPL). Optical density was measured at 450 nm (Bio-Rad Laboratories, Hercules, CA). A standard curve developed from the serum of a previously vaccinated animal, which has been shown to have a strong response to the vaccine, was used for the determination of relative ELISA units. The standard curve was constructed on every plate and used to calculate the relative serum antibody concentrations (expressed as ELISA units) by comparison with the standard curve constructed using the dilutions of the positive control serum.
Antibody Production: Equine Influenza (KY2002). Influenza-specific antibody production was evaluated by means of a hemagglutination inhibition (HI) assay, as well as an ELISA assay. The equine influenza virus (KY2002) used for the HI assay was prepared using 10-d-old embryonated chicken eggs. The virus was then concentrated by means of polyethylene glycol precipitation and purified by sucrose gradient centrifugation as described by Adams et al. (2011) .
Equine influenza (KY2002) antibodies [IgGa, IgGb, and IgG(T)] were measured using an ELISA assay. The 96-well plates (Immulon 1B microtiter plates; Fisher Scientific) were coated overnight at 4°C with 10 hemagglutination units per well of purified influenza virus (KY2002). The coated plates were then washed with PBS-T (Sigma) and blocked with 2% nonfat dried milk powder dissolved in PBS-T (Sigma) for 1 h at 37°C. Serum samples (diluted in PBS-T at 1:100) were added after the blocking and washing step. Plates were incubated for 1 h at 37°C. Plates were then washed with PBS-T and incubated for 1 h at 37°C with monoclonal antibodies specific for IgGa (CVS 40), IgGb (CVS 39), and IgG(T) (CVS 48). After another wash cycle with PBS-T (Sigma), plates were again incubated with the secondary antibody (horseradish peroxidase-conjugated goat-antimouse IgG antibody; Jackson Laboratories Inc., West Grove, PA) for 1 h at 37°C. Again, plates were washed, substrate (3,3′,5,5′-tetramethylbenzidine; Sureblue TMB 1; KPL) was added, and color was developed for 5 min. The reaction was stopped (TMB Stop Solution; KPL), and the optical density was determined at 450 nm using a 96-well plate reader (Bio-Rad Laboratories). A standard curve was constructed using serial dilutions of a serum sample from an influenza virus hyperimmune horse. This allowed for the calculation of relative antigen-specific antibody concentrations in all experimental serum samples. Relative serum antibody concentrations expressed as ELISA units were calculated by comparison with the standard curve.
For equine influenza HI assay each serum sample was trypsin-periodate treated to remove nonspecific inhibitors of virus hemagglutination, which are present in serum samples. This was done by adding 100 μL trypsin to 100 μL serum, followed by 30 min incubation in a 56°C water bath. Then 300 μL periodate were added, and samples were incubated at room temperature for 15 min, followed by the addition of 500 μL 0.6% glycerol in saline. This yielded a final serum dilution of 1:10. Then, 25 μL PBS was added to all the wells of a roundbottom 96-well plate (U-bottom microtiter vinyl plate, Fisher Scientific). Then 50 μL of the treated serum were added to the first well on the plate, and 25 μL were titrated across the row. Finally, 25 μL of virus (1:8 dilution) were then added to all wells. Plates were incubated for 30 min at room temperature. Buttons of nonagglutination were then read, and the titer was allocated to the last nonagglutinating dilution for each sample.
Statistical Analysis
Immunological data were analyzed as repeated-measures ANOVA using the Proc MIXED procedure (SAS Inst. Inc., Cary, NC) with least squares means separation procedure. The individual horse was used as the experimental unit. The model included time (sampling times during the vaccine challenge), treatment, block (age and gender), and treatment × time as fixed effects, whereas horse was included as a random effect. Data were tested for normality and log transformed when required for statistical analysis. Data were back transformed and are presented in tables and figures as least squares means. The whole blood Se concentration, GSH-Px, and serum vitamin E concentration were analyzed using ANOVA. Significance was set at P < 0.05 and a trend at P < 0.10.
RESULTS

Selenium and Vitamin E Status and CBC Data
At the initiation of the vaccine challenge, whole blood Se concentration and whole blood GSH-Px activity (Table 2) were greater for SP and SS when compared with AS (P < 0.05), which had greater whole blood Se (P < 0.05) but not GSH-Px activity than LS. Serum vitamin E concentration was similar across treatment groups. The CBC data (Table 3 ) collected during the vaccination period indicated no effect of treatment or treatment × time on lymphocyte numbers, neutrophil numbers, or the ratio of lymphocytes to neutrophils.
Vaccination Response
The anti-OVA-IgG values (Fig. 2) indicated a trend for an effect of treatment (P = 0.066), an effect of time (P < 0.001), and a treatment × time interaction (P = 0.007). The second vaccine elicited a stronger antibody response (wk 4, 5, 6, and 7) in all treatment groups. At wk 4, LS and SS antibody concentrations were similar but greater than AS and SP (P < 0.05). At wk 5, 6, and 7, antibody production was comparable between LS, SP, and SS, but LS and SS had greater antibody concentrations than AS (P < 0.05). Lymphocyte proliferation in response to OVA stimulation was similar among the different treatments (Table 4 ). The intracellular production of IFNγ and TNFα in response to in vitro OVA stimulation, measured by flow cytometry, indicated no effect of Se status on the percentage of lymphocytes producing IFNγ (treatment, P = 0.801; time, P = 0.605; treatment × time, P = 0.490; data not shown) or TNFα (treatment, P = 0.441; time, P = 0.009; treatment × time, P = 0.424; data not shown). However, a greater (treatment, P = 0.031) MFI was observed for IFNγ in LS when compared with AS and SP, whereas MFI was comparable between LS and SS (data not shown). Similarly, the PBMC mRNA expression of cytokines in response to OVA stimulation (data not shown) indicated no effect of Se status on any of the cytokines evaluated. S erum vitamin E, µg/mL 3.6 ± 0.5 3.8 ± 0.5 3.8 ± 0.5 3.9 ± 0.5 0.988 a-c Means within row lacking a common superscript differ (P < 0.05).
The humoral immune response to the influenza vaccination is presented in Table 5 . Although there was an effect of time on IgGa (P < 0.001), IgGb (P < 0.001), IgGT (P = 0.025), and the influenza titer (P < 0.001), no effects of treatment or treatment × time interactions were observed. Lymphocyte proliferation in response to in vitro influenza stimulation was also not affected by treatment. In addition, mRNA cytokine expression of PBMC stimulated in vitro with influenza and intracellular production of IFNγ and TNFα was also unaffected by treatment (data not shown).
General Immune Response
Lymphocyte proliferation in response to ConA stimulation indicated no difference in the ability of the lymphocytes to proliferate, regardless of dietary treatment, as indicated before (Table 4) . Intracellular production of IFNγ and TNFα in lymphocytes stimulated with PMA was also unaffected by treatment (data not shown). In contrast, the PBMC mRNA expression of several cytokines stimulated in vitro with PMA (Table 6 ) indicated suppressed expression of specific cytokines in LS cells. The LS group had decreased expression of IL-8 and IL-13 compared with AS, SP, and SS (P < 0.05). The over- all mRNA expression of IL-1 was also reduced in LS compared with AS and SS (P < 0.05). A treatment by time interaction existed for IL-6 (P < 0.001) and IL-10 (P < 0.001), indicating a decreased expression of IL-6 in LS when compared with AS and SP at all time points and decreased IL-10 expression compared with AS, SP, and SS at wk 0 and 5. The mRNA expression of IL-10 was reduced in SS compared with the other 3 treatment groups at wk 3. The mRNA expression of IL-6 and IL-10 was greater in SP than SS but comparable to AS. In addition a treatment × time interaction existed for IFNγ (P < 0.001) and IL-2 (P = 0.003), indicating greater expression of IFNγ at wk 3 for SP and LS compared with SS and AS and decreased IL-2 at wk 3 for SS compared with SP, AS, and LS. The mRNA expression of GrzB was unaffected by Se status (data not shown). Unstimulated whole blood mRNA expression of selected cytokines (Table 7) indicated an overall greater expression of IL-10 for SS compared with other treatment groups (P < 0.05). A trend for treatment × time interaction (P = 0.057) was observed for IL-6. Separation of means revealed IL-6 expression of SP to be reduced at wk 0 compared with LS but similar to AS and SS. In addition IL-6 mRNA expression remained similar across all time points for LS and AS but increased from wk 0 to 3 in SP and SS (time, P = 0.03).
DISCUSSION
Supplementation with Se has been reported to affect immune function across species, including cattle, sheep, goats, and humans (Finch and Turner, 1996; McKenzie et al., 1998; Broome et al., 2004) . In ponies, low Se status has also been shown to affect antibody response (Knight and Tyznik, 1990) . Therefore, we were interested in evaluating the effect of Se supplementation on immune function in horses that were of low, adequate, or high Se status. After 22 wk on the supplemented diets, the whole blood Se concentrations and GSH-Px activity in groups receiving 0.06, 0.12, or 0.3 mg Se/kg DM reflected the different dietary Se intakes. The reference range for adequate whole blood Se concentration is 180 to 240 ng/mL (Stowe, 1998) . At the onset of the vaccine challenge the range of Se concentrations between dietary treatments were as follows: LS, 101 to 149 ng/ mL; AS, 168 to 202 ng/mL; SP, 232 to 278 ng/mL; and SS, 232 to 281 ng/mL. Therefore, horses in the LS group had whole blood Se concentrations below the reference range, horses in the AS group were at the lower end of the reference range, and horses in SP and SS had whole blood Se concentrations at the upper end or above that of the reference range. Whole blood GSH-Px activity was measured as a biological indicator of Se status and was also reflective of whole blood Se concentrations. In addition, serum vitamin E concentrations were similar among treatments and indicative of adequate vitamin E status. Vitamin E status has been linked to immune function (Meydani et al., 1990; Beck, 2007) . Therefore, a similar vitamin E status across treatments was important to ensure correct interpretation of the immune response results. On the basis of the aforementioned variables, our experimental model responded as hypothesized, and therefore, the immune variable response was anticipated to present an accurate representation of the effect of Se status on immune function.
Vaccination response was assessed using OVA and equine influenza as antigens. These antigens allowed the evaluation of both primary and memory vaccination response on an in vivo (humoral response) and in vitro (antigen-specific cell-mediated response) basis. The OVA-specific antibody response followed the expected pattern of response as a small increase in antibody production was observed in response to the first vaccine, followed by a much stronger antibody response after administration of the second vaccine at 3 wk. The antibody response to the initial OVA vaccination was similar among treatments. After the second vaccination, the AS a-c For each item, means within a column lacking a common superscript differ (P < 0.05).
1 T-bet = T-box expressed in T cells; GATA-3 = GATA binding protein-3; IFNγ = interferon-γ; TNFα = tumor necrosis factor-α.
2 Data were log transformed for statistical analysis. Data are presented as least squares means.
3 Dietary treatments (total dietary Se): LS = low Se (0.06 mg Se/kg DM); AS = adequate Se (0.12 mg Se/kg DM); SP = organic Se (0.3 mg Se/kg DM, SelPlex, Alltech Inc., Nicholasville, KY); SS = inorganic Se (0.3 mg Se/kg DM, sodium selenite). The AS, LS, and SS groups consisted of 6 horses each, whereas the SP group consisted of 7 horses. 4 Mean within treatment across all vaccination sample time points.
group did not appear to have a strong antibody response, as indicated by decreased antibody response compared at specific time points. The reason for the reduced antibody response in AS is unknown. Comparing only the horses of adequate (AS, 0.12 mg/kg DM) and high (SP and SS, 0.3 mg/kg DM) Se status, it would therefore appear as if greater Se intake supported greater antibody production. However, as antibody production was similar among the horses of low (LS, 0.06 mg/kg DM) and high (SP and SS, 0.3 mg/kg DM) Se status, it is difficult to substantiate an advantage of greater levels of dietary Se intake in terms of antibody production. Therefore, we concluded that Se status did not have an effect on antibody production in this study. Improved antibody concentrations have been associated with Se supplementation in lambs, ponies, and quail (Reffett et al., 1988; Knight and Tyznik, 1990; Biswas et al., 2006) , although it should be noted that the low-Se control treatment group in the study conducted by Knight and Tyznik (1990) using ponies had lower Se intake (0.02 mg Se/kg) than our low-Se group (0.06 mg Se/kg). In our study, the lack of effect of Se status on the primary antibody response was also in contrast to previous work from our laboratory that indicated decreased primary antibody response in horses of low Se status compared with horses of adequate Se status (Brummer et al., 2011) . This may relate to the longer period of time that the LS horses had received a low-Se diet at the time of this vaccine challenge (approximately 14 mo when accounting for initial depletion phase), compared with the previously reported study where the vaccine challenge was administered after 7 mo on the low-Se diet (Brummer et al., 2011) . This may indicate an adaptation to the lower dietary Se intake, possibly through compensation by other components of the antioxidant system, such as vitamin E. Similar to the current study, Baalsrud and Overnes (1986) reported comparable antibody production in response to vaccination between horses on a Se-supplemented (0.5 mg Se/kg DM) or a low-Se and low-vitamin E control diet (0.03 mg Se/kg DM, 18 mg α-tocopheryl acetate/kg DM). However, horses receiving a combination of Se and vitamin E supplementation (0.5 mg/kg DM, 80 mg α-tocopheryl acetate/kg DM) reportedly had improved antibody production compared For each item, means within a column lacking a common superscript differ (P < 0.05).
1 IFNγ = interferon-γ; TNFα = tumor necrosis factor-α. with the low-Se and vitamin E control group (Baalsrud and Overnes, 1986) . Therefore, it is plausible that the adequate vitamin E status of our horses allowed for a normal antibody response to vaccination, even in the horses of low Se status. In addition, influenza-specific antibody production and influenza titers were also unaffected by Se status, supporting the potential role of adequate vitamin E status in supporting adequate antibody response when Se status is low. The CBC analysis conducted throughout the vaccination period served to monitor the overall health of the horses and to evaluate lymphocyte and neutrophil numbers. Changes in lymphocyte numbers in response to Se supplementation in the horse have been reported (Calamari et al., 2010) . However, in this study, Se status did not affect any of these variables. Therefore, differences observed in immune response would likely not be due to altered lymphocyte or neutrophil numbers in vivo.
Antigen-specific cell-mediated measures of immune function were evaluated by means of in vitro stimulation of PBMC with OVA and equine influenza. When using in vitro methods to assess the effect of a nutrient on immune function, the nutrient composition of the culture media is of utmost importance (Fraker, 1994) . To better reflect the in vivo environment in such studies, the use of autologous serum is thought to be more appropriate (Fraker, 1994) and has indeed been shown to affect lymphocyte proliferation results in pigs deficient in either Se or vitamin E (Lessard et al., 1991) . Therefore, heat-inactivated autologous serum was used in the culture media for all the in vitro stimulation assays.
Lymphocyte proliferation in response to OVA stimulation did not exhibit an effect of Se status on observed response. In addition, the prevaccination proliferation response was similar to the postvaccination proliferative response, indicating no effect of OVA vaccination on in vitro measures of OVA-stimulated lymphocyte proliferation. Lymphocyte proliferation in response to influenza stimulation was also unaffected by Se status. In contrast, enhanced proliferation in response to in vitro stimulation with polio virus has been reported in human subjects supplemented with Se compared with placebo controls (Broome et al., 2004) . Similarly, other studies have also reported associations between Se supplementation and increased proliferation in response to mitogen stimulation (Lessard et al., 1991; Peretz et al., 1991; Roy et al., 1994) . In contrast to these reports but similar to the current study, previous research from our laboratory also indicated no effect of Se status on equine lymphocyte proliferation (Brummer et al., 2009 (Brummer et al., , 2011 . Recently, lymphocyte proliferation was reported to be similar between foals of 1 mo of age, regardless of the source of Se (sodium selenite or Se-yeast) fed to their dams (Montgomery et al., 2012). It has been suggested that lymphocyte proliferation is enhanced by Se supplementation because of the role of Se in the modulation of the arachidonic acid metabolism (Cao et al., 1992) . Using in vitro assays with bovine cells, the authors reported that low Se status was associated with a reduction in the metabolites of the 5-lipoxygenase pathway, which in turn was linked to decreased lymphocyte proliferation. The suppressed proliferation response was reportedly reversed by the addition of specific lipoxygenase pathway products (Cao et al., 1992) . Collectively, our results indicate that lymphocyte proliferation in the horse may not be as sensitive to Se status as reported in other species, that differences in proliferation may be too small to detect, or that the responses among horses were too variable.
Intracellular production of IFNγ and TNFα indicated that although the number of IFNγ-producing cells was not affected by Se status, the amount of IFNγ produced by these lymphocytes (MFI) was greater for the LS group. Yet Se status did not affect the relative mRNA expression of IFNγ. Similarly, Se status had no effect on the relative expression of any of the other cytokines and transcription factors in OVA-or influenza-stimulated PBMC. These results indicate that Se status only had limited effects on the cell-mediated response to vaccination, whether a novel or previously administered vaccine was used. However, together with the lymphocyte proliferation results, comparing prevaccination response to post vaccination response data suggests that the OVA have a strong effect on any of the OVA-specific cell-mediated variables. This potentially indicates that the previously tested in vitro OVA stimulation protocol used in this study did not sufficiently stimulate the PBMC in vitro to induce detectable change, or OVA induced a stronger effect on the humoral component of the immune system. In addition, previous work indicated reduced expression of the transcription factor T-bet in horses of low Se status compared with horses of adequate Se status in response to vaccination with keyhole limpet hemocyanin (Brummer et al., 2011) . That response was also not observed here. Therefore, it is difficult to interpret the effect of Se status on the OVA vaccination response in this study.
However, we also evaluated cell-mediated immune function by assessing response to nonspecific mitogen stimulation in vitro. Mitogen stimulation is nonspecific and targets a large proportion of the cells in culture, as opposed to highly specific antigen stimulation (Calder, 2007) . The use of mitogens also provides a measure of the functional capacity of cells (Touraine et al., 1977; Vance et al., 2004) .
Differences were observed in the relative mRNA expression of several cytokines. Overall, LS had lower relative expression of IL-8 and IL-13 compared with AS, SP, and SS. Interleukin-8 is a cytokine that functions as a neutrophil chemoattractant and activator of the degranu-lation of neutrophils (Dinarello, 2000) . Wuryastuti et al. (1993) reported reduced phagocytic and microbicidal ability of neutrophils isolated from Se-deficient sows, whereas Aziz and Klesius (1985) reported Se deficiency affected the ability of lymphocytes to modulate neutrophil migration. Therefore, the decreased expression of IL-8 upon stimulation with PMA in the LS group was an interesting observation. Unfortunately, we did not conduct any measures of neutrophil function, but the effect of Se status on IL-8 indicates that this should be included in future studies. The cytokine IL-13 is associated with the regulation of cell-mediated responses (Tato and Cua, 2008) , but the decreased expression of IL-13 in LS is in contrast to Beck et al. (2001) , who reported that mRNA abundances of IL-13 were increased in Se-deficient mice by d 6 postvaccination with an influenza virus strain when compared with Se-adequate mice. These authors also reported increased IL-4, IL-5, IL-10, and IL-13 from d 14 onward, the opposite of what they expected after a viral challenge (Beck et al., 2001 ). In the current study, IL-6 and IL-10 were also decreased in LS compared with AS and SP. In contrast to Beck et al. (2001) , our results did not indicate a change in the pattern of cytokine response in the LS horses, but rather an overall suppressed mRNA expression of several cytokines after PMA stimulation, indicating that the functional ability of the PBMC to respond may be hindered by low Se status.
Relative mRNA expression of cytokines in unstimulated whole blood provides an in vivo measure of cytokine production in the horse. Here, in contrast to the stimulated PBMC results, the relative expression of IL-10 was greater in SS compared with LS, AS, and SP. The cytokine IL-10 is described as one of the most important anti-inflammatory cytokines (Opal and DePalo, 2000) . Interleukin-10 is produced by the B cells and Thelper (Th) cells involved in the humoral response (Th2; Goldsby et al., 2000) and downregulates the Th1 cells that provide defense against intracellular pathogen response via IL-2 and IFNγ production (Opal and DePalo, 2000) . Although IFNγ expression in the unstimulated whole blood samples was similar across treatments, the SS treatment group did have a strong humoral (Th2) response to the OVA vaccination. A trend also existed for the relative expression of IL-6 to increase from wk 0 to 3 in SP and SS. Although IL-6 is a cytokine with both pro-and anti-inflammatory properties, it can be regarded as anti-inflammatory because of its ability to downregulate TNFα and IL-1. In our study, unstimulated whole blood expression of TNFα was unaffected by Se status. In mice, TNFα expression in macrophages from LPS stimulated lung cells was found to be reduced in the Se-adequate mice compared with mice of low Se status (Vunta et al., 2008) .
Comparing the effect of source of Se supplementation, the SP group had a greater PBMC mRNA expression of IFNγ and IL-2 at wk 3 in response to PMA stimulation compared with SS, whereas SS elicited a stronger humoral response to OVA immediately after this time point. Although OVA-specific stimulation at this time indicated no difference between IFNγ and IL-2 for SS and SP, PMA stimulation indicates a stronger Th1 type of response in SP at wk 3, whereas the greater antibody production, together with greater in vivo IL-10 expression after this time point in SS, may indicate a stronger humoral (Th2) response in SS.
The mechanism of action of Se on the immune system is a subject that has received considerable interest, yet the exact mechanism remains elusive. The role of NF-κβ has been considered. The NF-κβ is a transcription factor that initiates the transcription of cytokines, specifically, the proinflammatory cytokines (Tosi, 2005) , including the production of proinflammatory proteins such as TNFα and IL-6 (Duntas, 2009) . It has been hypothesized that the antioxidant properties of Se prevent the overactivation of NF-κβ by high levels of reactive oxygen species (ROS; Beck et al., 2001; Zeng and Combs, 2008) . In our study, LS had lower GSH-Px activity, which could potentially result in greater ROS concentrations, but TNFα and IL-6 were not increased in LS. Another proposed mechanism suggests that a greater Se intake may improve T-cell receptor strength signaling via increased Ca 2+ flux (Hoffmann et al., 2010) . Recently, a study using selenoprotein K knockout mice also indicated that the mechanism of action for Se and the immune system may lie in the regulation of Ca 2+ flux, implicating the importance of selenoprotein K in immune function (Verma et al., 2011) . In our study, the PMA/ionomycin (calcium ionophore) stimulation protocol results in the activation of PBMC via activation of the protein kinase C as well as calcium signaling pathways. The overall suppressed cytokine mRNA expression observed for the low-Se group despite the addition of ionomycin to the cultures may support these proposed mechanisms of action.
In conclusion, our study indicated that Se status, either high or low, did not affect the ability of the horses to mount an immune response to a novel antigen or to a previously administered antigen as measured by antigen-specific antibody production. However, cellmediated immunity, evaluated using in vitro mitogen stimulation, appeared suppressed in the horses of low Se status, as measured by relative mRNA expression of cytokines in PBMC. In addition, in vivo relative cytokine gene expression was also affected by Se status. No clear advantage in immune function was observed comparing supplementation at 0.12 with 0.3 mg/kg DM, although AS did have lower antibody production. Collectively,
